Atossa Therapeutics Targets Lucrative Market: Nasal Spray for Early Onset, Mild to Moderate COVID-19 & Prophylaxis

Atossa Therapeutics Targets Lucrative Market Nasal Spray for Early Onset, Mild to Moderate COVID-19 & Prophylaxis

A Seattle-based biotech company announced the results of its early stage, Phase 1 clinical trial investigating the safety of a drug candidate known as AT-301 administered by nasal spray. Considered safe and tolerated in healthy male and female participants, this study included two dose levels over 14 days. Under investigation for at home use targeting COVID-19, there are presently no such treatments authorized by the U.S. Food and Drug Administration (FDA). Now they will proceed to Phase 2 studies this quarter.   

TrialSite provides a brief summary breakdown of this update.

Who is the trial sponsor?

Named after a Persian Queen that happened to be the very first women in recorded history with breast cancer, Atossa Therapeutics, Inc. trades under the symbol ATOS in Nasdaq. They are a clinical-stage biotech company pursuing the development of medicines in areas of significant unmet need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.

Founded in 2009, the company has raised about $32 million, according to Crunchbase, pricing $20 million during an investment process during December, 2020. As with most small biotech, they represe...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee